NCT03703297: A trial that was reported late by AstraZeneca
This trial has reported, although it was 128 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03703297 |
|---|---|
| Title | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 27, 2018 |
| Completion date | Jan. 15, 2024 |
| Required reporting date | Jan. 14, 2025, midnight |
| Actual reporting date | May 23, 2025 |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | 128 |